Conflicting results have been reported on the potential role of Tumor Mutational Burden (TMB) as predictive biomarker for immune checkpoint inhibitors. However, the recent approval of TMB as agnostic biomarker for pembrolizumab in previously treated patients with solid tumors is increasing the interest of laboratories to provide this test. In this scenario, the harmonization of read more…